中山大便后肛门出血疼痛中山疵疮的症状,中山肛门肿包,中山便血鲜血,中山哪个医院脱肛最好,中山生孩子得痔疮,中山上火屁股出血,中山肛门硬疙瘩

BEIJING, May 10 (Xinhuanet) -- Professional social networking site LinkedIn is aiming for a valuation of 3.3 billion U.S. dollars for its initial public offering, media reports said Tuesday.The Mountain View, California-based company is expected to begin trading on the New York Stock Exchange within the next month and will use the symbol "LNKD."It plans to offer 7.84 million shares priced at 32 dollars to 35 dollars each, according to the filing, which it submitted to the Securities and Exchange Commission.LinkedIn, which has more than 100 million members in over 200 countries and territories, is seeking to raise as much as 274.4 million dollars from the initial public offering (IPO) with 146.6 million dollars going to the company itself.In 2010, LinkedIn made 15 million dollars in profit on 243 million dollars in revenue, according to the filing.LinkedIn's biggest shareholder is its founder and chairman, Reid Hoffman, who owns more than 21 percent of the company.

JERUSALEM, March 31 (Xinhua) -- Two researchers at the Hebrew University (HU) of Jerusalem have been honored with a prestigious award for their study of the connection between several inflammatory diseases, cancer and bacteria.Medical faculty members, Dr. Eli Pilarsky and Prof. Sigal Ben- Yehuda, won this year's Sir Zelman Cowen Universities Fund prize that recognizes significant achievement in the field of medicine.The prize committee noted the impressive contributions of Pilarsky and Ben-Yehuda in understanding complex diseases like cancer and antibiotic-resistant infections, and, in a first, decided to award the two scientists this year.Pilarsky told Xinhua that his research deals with the connection between chronic inflammatory diseases like hepatitis, and the development of cancer cells."The relevance of this discovery is that we were able to establish the link between the molecules secreted with such inflammations and the proliferation of cancer cells," Pilarsky explained, noting that "we discovered that the inflammation favors the cancer cells' growth, and now we are trying to find a way to manipulate these molecules to stop the cancer cells from appearing. ""The importance of these findings lies in the fact that 20 percent of the world's cancer cases are attributed to inflammation processes," Pilarsky pointed out.

WASHINGTON, April 13 (Xinhua) -- The U.S. Food and Drug Administration (FDA) announced on Wednesday that it has approved the cPAX Aneurysm Treatment System for surgery on brain aneurysms that are difficult to manage because of their size and shape.An aneurysm is a bulge in the wall of a blood vessel, which can rupture as it increases in size, causing hemorrhage or death. Brain aneurysms often produce no symptoms until they grow and press on nerves in the brain, or until they begin to leak blood or rupture.Aneurysms can be repaired in two ways: surgeons can close the base of the aneurysm with a surgical clip, or use a technique commonly known as coiling, in which surgeons use a catheter to thread metallic coils through a blood vessel in the groin and into the blood vessel in the brain that contains the aneurysm. Surgeons then fill the aneurysm with the detachable coils, which block it from circulation and cause blood to clot, effectively destroying the aneurysm.Aneurysms larger than 10 millimeters are difficult to treat with clipping or coiling. The cPAX device system is indicated for use in those brain aneurysms."Like coiling, the cPAX Aneurysm Treatment System is a form of endovascular repair," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "But instead of tiny metallic coils, it uses a special polymer material to fill the space within the aneurysm."According to the FDA, the cPAX device system is indicated for use in adults aged 22 and older and should not be used in patients with an active infection or in those in whom anticoagulation and antiplatelet therapy is contraindicated.

WASHINGTON, May 11 (Xinhua) -- Researchers at Brigham and Women 's Hospital (BWH), a teaching affiliate of Harvard Medical School, have identified a human lung stem cell that is self-renewing and capable of forming and integrating multiple biological structures of the lung. This research will be published Thursday in the New England Journal of Medicine."This research describes, for the first time, a true human lung stem cell. The discovery of this stem cell has the potential to offer those who suffer from chronic lung diseases a totally novel treatment option by regenerating or repairing damaged areas of the lung," said the study's corresponding author Piero Anversa, who is also director of the Center for Regenerative Medicine at the hospital.Using lung tissue from surgical samples, researchers identified and isolated the human lung stem cell and tested the functionality of the stem cell both in vitro and in vivo. Once the stem cell was isolated, researchers demonstrated in vitro that the cell was capable of dividing both into new stem cells and also into cells that would grow into various types of lung tissue. Next, researchers injected the stem cell into mice with damaged lungs. The injected stem cells differentiated into new bronchioles, alveoli and pulmonary vessel cells which not only formed new lung tissue, but also integrated structurally to the existing lung tissue in the mice.The researchers define this cell as truly "stem" because it fulfills the three categories necessary to fall under stem cell categorization: first, the cell renews itself; second, it forms into many different types of lung cells; and third, it is transmissible, meaning that after a mouse was injected with the stem cells and responded by generating new tissue, researchers were then able to isolate the stem cell in the treated mouse, and use that cell in a new mouse with the same results."These are the critical first steps in developing clinical treatments for those with lung disease for which no therapies exist. Further research is needed, but we are excited about the impact this discovery could have on our ability to regenerate or recreate new lung tissues to replace damaged areas of the lungs," said Joseph Loscalzo, chair of the Department of Medicine at BWH and co-author.

BEIJING, Feb. 15 (Xinhua) -- China's health authorities Tuesday vowed to improve their response to food safety incidents.The ministry would issue a protocol "as early as possible" on how to respond to and investigate food safety incidents, said Vice Health Minister Chen Xiaohong at a national meeting on food safety in Beijing.It would also provide better training for officials and professionals working in the field, Chen said.Last year, the ministry initiated investigations into several incidents such as milk powder that allegedly caused infant girls to grow breasts and illegal soup additives by restaurants.In the milk powder case, the investigation found no evidence that Synutra International's products had caused the problem. Media reports said the company was the victim of dirty tricks by a rival firm.In addition, the ministry blacklisted 48 substances illegally added to food and 22 misused food additives last year.The ministry would include projects related to food safety in state-sponsored health programs giving free medical services to the public in next five years, Health Minister Chen Zhu said at the same meeting.But Chen did not give details about what kind of projects they will be.Under the current six state health programs, the government provides free cataract surgery for the needy, free breast and cervical examinations for rural women, free hepatitis B vaccines, free folic acid pills for rural women, new cooking stoves in rural homes to prevent fluorine poisoning caused by coal stoves as well as modern toilets for rural residents.